Advertisement

Lysyl oxidase (LOX) down-regulation by TNFα: A new mechanism underlying TNFα-induced endothelial dysfunction

      Abstract

      Objective

      TNFα is a pro-inflammatory cytokine that induces endothelial dysfunction and promotes atherosclerosis progression. Down-regulation of lysyl oxidase (LOX), a key enzyme in extracellular matrix maturation, by pro-atherogenic risk factors such as LDL and homocysteine, is associated with an impairment of endothelial barrier function. Our hypothesis is that the inflammatory cytokine TNFα could also modulate LOX expression/function in endothelial cells.

      Methods

      The study was carried out in human umbilical vein endothelial cells (HUVEC), porcine aortic endothelial cells (PAEC) and bovine aortic endothelial cells (BAEC). LOX mRNA levels were analysed by real-time PCR and LOX activity was assessed by a high sensitive fluorescent assay. Promoter activity was determined by transient transfection using a luciferase reporter system.

      Results

      TNFα decreases LOX mRNA levels in endothelial cells in a dose- and time-dependent manner. The effect of TNFα was observed at low concentrations (0.1–1 ng/mL) and was maximal at 2.5 ng/mL (after 21 h). In transfection assays, TNFα reduced LOX transcriptional activity to a similar extent than LOX mRNA. Furthermore, TNFα decreases endothelial LOX enzymatic activity. By using both TNF receptor (TNFR) agonist and blocking antibodies we determined the involvement of TNFR2 on LOX down-regulation. Moreover, while TNFR-associated factor-2 (TRAF-2) did not mediate signalling events leading to LOX inhibition, PKC inhibitors counteracted the TNFα-induced decrease of LOX mRNA levels. Finally, TNFα administration significantly reduced vascular LOX expression in rat aorta.

      Conclusions

      Endothelial dysfunction induced by TNFα is associated with a decrease of LOX expression/activity. Thus, LOX seems to be involved in the impairment of endothelial function triggered by different pathological conditions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mehta J.L.
        • Li D.Y.
        Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?.
        Cardiovasc Res. 1999; 43: 291-299
        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Fiichtlscherer S.
        • Rossig L.
        • Breuer S.
        • Vasa M.
        • Dimmeler S.
        • Zeiher A.M.
        Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure.
        Circulation. 2001; 104: 3023-3025
        • Agnoletti L.
        • Curello S.
        • Bachetti T.
        • et al.
        Serum from patients with severe heart failure down-regulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha.
        Circulation. 1999; 100: 1983-1991
        • Wang P.
        • Ba Z.F.
        • Chaudry I.H.
        Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation.
        Am J Physiol. 1994; 266: H2535-H2541
        • Ferro T.
        • Neumann P.
        • Gertzberg N.
        • Clements R.
        • Johnson A.
        Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha.
        Am J Physiol Lung Cell Mol Physiol. 2000; 278: L1107-L1117
        • Krasinski K.
        • Spyridopoulos I.
        • Kearney M.
        • Losordo D.W.
        In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty.
        Circulation. 2001; 104: 1754-1756
        • Picchi A.
        • Gao X.
        • Belmadani S.
        • et al.
        Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome.
        Circ Res. 2006; 99: 69-77
        • Nystrom T.
        • Nygren A.
        • Sjoholm A.
        Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction.
        Clin Sci (Lond). 2006; 110: 673-681
        • Mann D.L.
        Targeted anticytokine therapy and the failing heart.
        Am J Cardiol. 2005; 95: 9C-16C
        • Kagan H.M.
        • Li W.
        Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell.
        J Cell Biochem. 2003; 88: 660-672
        • Erler J.T.
        • Bennewith K.L.
        • Nicolau M.
        • et al.
        Lysyl oxidase is essential for hypoxia-induced metastasis.
        Nature. 2006; 440: 1222-1226
        • Song Y.L.
        • Ford J.W.
        • Gordon D.
        • Shanley C.J.
        Regulation of lysyl oxidase by interferon-γ in rat aortic smooth muscle cells.
        Arterioscler Thromb Vasc Biol. 2000; 20: 982-988
        • Maki J.M.
        • Rasanen J.
        • Tikkanen H.
        • et al.
        Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction and perinatal death in mice.
        Circulation. 2002; 106: 2503-2509
        • Rodríguez C.
        • Raposo B.
        • Martínez-González J.
        • Casani L.
        • Badimon L.
        Low density lipoproteins down-regulates lysyl oxidase in vascular endothelial cells and the arterial wall.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1409-1414
        • Raposo B.
        • Rodríguez C.
        • Martínez-González J.
        • Badimon L.
        High levels of homocysteine inhibit lysyl oxidase (LOX) and down-regulates LOX expression in vascular endothelial cells.
        Atherosclerosis. 2004; 177: 1-8
        • Rodríguez C.
        • Martínez-González J.
        • Sánchez-Gómez S.
        • Badimon L.
        LDL down-regulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism.
        Circ Res. 2001; 88: 268-274
        • Rodríguez C.
        • Raposo B.
        • Martínez-González J.
        • Llorente-Cortes V.
        • Vilahur G.
        • Badimon L.
        Modulation of ERG25 expression by LDL in vascular cells.
        Cardiovasc Res. 2003; 58: 178-185
        • Martínez-González J.
        • Raposo B.
        • Rodríguez C.
        • Badimon L.
        3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase down-regulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation.
        Arterioscler Thromb Vasc Biol. 2001; 21: 804-809
        • García-Ramírez M.
        • Martínez-González J.
        • Juan-Babot J.O.
        • Rodríguez C.
        • Badimon L.
        Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth.
        Arterioscler Thromb Vasc Biol. 2005; 25: 2398-2403
        • Masaki T.
        • Yoshimatsu H.
        • Kakuma T.
        • et al.
        Induction of rat uncoupling protein-2 gene treated with tumour necrosis factor alpha in vivo.
        Eur J Clin Invest. 1999; 29: 76-82
        • Hornstra I.K.
        • Birge S.
        • Starcher B.
        • Bailey A.J.
        • Mecham R.P.
        • Shapiro S.D.
        Lysyl oxidase is required for vascular and diaphragmatic development in mice.
        J Biol Chem. 2003; 278: 14387-14393
        • Huffman M.D.
        • Curci J.A.
        • Moore G.
        • Kerns D.B.
        • Starcher B.C.
        • Thompson R.W.
        Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms.
        Surgery. 2000; 128: 429-438
        • Sullivan C.J.
        • Teal T.H.
        • Luttrell I.P.
        • Tran K.B.
        • Peters M.A.
        • Wessells H.
        Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats.
        Physiol Genomics. 2005; 23: 192-205
        • Pischon N.
        • Darbois L.M.
        • Palamakumbura A.H.
        • Kessler E.
        • Trackman P.C.
        Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts.
        J Biol Chem. 2004; 279: 30060-30065
        • Kishore R.
        • Luedemann C.
        • Bord E.
        • Goukassian D.
        • Losordo D.W.
        Tumor necrosis factor-mediated E2F1 suppression in endothelial cells: differential requirement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signal transduction pathways.
        Circ Res. 2003; 93: 932-940
        • Kishore R.
        • Qin G.
        • Luedemann C.
        • et al.
        The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A.
        J Clin Invest. 2005; 115: 1785-1796
        • Min W.
        • Pober J.S.
        TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways.
        J Immunol. 1997; 159: 3508-3518
        • Pohlman T.H.
        • Harlan J.M.
        Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis.
        Cell Immunol. 1989; 119: 41-52
        • MacEwan D.J.
        TNF receptor subtype signalling: differences and cellular consequences.
        Cell Signal. 2002; 14: 477-492
        • Corredor J.
        • Yan F.
        • Shen C.C.
        • et al.
        Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms.
        Am J Physiol Cell Physiol. 2003; 284: C953-C961
        • Pan S.
        • An P.
        • Zhang R.
        • He X.
        • Yin G.
        • Min W.
        Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis.
        Mol Cell Biol. 2002; 22: 7512-7523
        • Grech A.P.
        • Gardam S.
        • Chan T.
        • et al.
        Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site.
        J Biol Chem. 2005; 280: 31572-31581